News

STAT1d

Pharmalittle: We’re reading about a new Novo Nordisk CEO, an FDA reversal on Sarepta, and more

Novo Nordisk tapped Maziar Mike Doustdar, its head of international operations, as its new chief executive officer and ...

Healthcare earnings: UnitedHealth delays, Sarepta's FDA probe

UnitedHealth (UNH) delayed its earnings report amid rising medical costs and is now set to report second quarter results on ...
BioPharma Dive9d

5 questions on Sarepta, the FDA and a Duchenne gene therapy crisis

While Sarepta has now consented to the FDA’s request to stop selling Elevidys, the company’s brief standoff with the agency ...
Benzinga.com1mon

Did The FDA Make A Mistake? Sarepta's Elevidys Approval ... - Benzinga

For a broader perspective on Sarepta’s outlook, explore how other analysts view the stock. Price Action: SRPT stock is trading lower by 9.96% to $17.09 at last check Wednesday. Read Next: ...
GEN - Genetic Engineering and Biotechnology News13d

Sarepta Axes 500, 36% of Workforce, in Restructuring after DMD Patient Deaths

Sarepta Therapeutics said it will eliminate 36% of its workforce—approximately 500 jobs—in a restructuring that follows the deaths of two Duchenne muscular dystrophy (DMD) patients following treatment ...
Fierce Biotech14d

Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning

Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...
Morningstar27d

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates ... - Morningstar

On this news, Sarepta's stock price fell $4.18 per share, or 7.13%, to close at $54.43 per share on April 4, 2025. Next, on June 15, 2025, Sarepta disclosed a second patient had died of acute ...